What is Ziplyft?
Ziplyft, operating under the OSHERU umbrella, is a medical technology firm dedicated to advancing eyelid procedures through its patented, minimally invasive device. The company addresses a critical gap in the market by providing a solution that enhances both visual field functionality and aesthetic outcomes while significantly reducing patient recovery time and procedural discomfort.
By targeting both specialized surgeons and patients seeking efficient, low-downtime alternatives to traditional blepharoplasty, Ziplyft is effectively positioning itself as a leader in modern oculoplastic innovation. The company's focus on accessibility and procedural efficiency aligns with broader trends in healthcare, where the demand for outpatient, high-precision surgical tools continues to rise.
How much funding has Ziplyft raised?
Ziplyft has raised a total of $4.7M across 1 funding round:
Angel/Seed
$4.7M
Angel/Seed (2024): $4.7M with participation from Laboratorios Sophia and Phil Knight
Key Investors in Ziplyft
Laboratorios Sophia
Sophia Innovation Capital is a pharmaceutical-focused investment entity that leverages deep industry expertise to support high-growth medical technology ventures.
Phil Knight
An independent specialist in geospatial systems and data analysis, providing strategic support and technical oversight for complex project infrastructures.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Ziplyft?
With this major enterprise-level funding, Ziplyft is poised to expand its clinical reach and operational infrastructure. The strategic roadmap likely includes scaling manufacturing capabilities to meet anticipated demand and investing in clinical validation studies to further substantiate the efficacy of the Ziplyft device. As the company moves forward, it will likely focus on strengthening its distribution networks and fostering partnerships with leading ophthalmic and plastic surgery centers globally.
The current capital structure provides the necessary runway to navigate regulatory milestones and enhance product development, ensuring that Ziplyft remains at the forefront of the minimally invasive surgery sector. Future growth will be defined by the company's ability to translate this financial momentum into widespread clinical adoption and sustained market leadership.
